M. Hixon

发表

Salicylanilide analog minimizes relapse of Clostridioides difficile infection in mice.

K. Janda, Steven Blake, R. Thanissery, 2020, Journal of medicinal chemistry.

Quo vadis photorespiration: A tale of two aldolases

W. Fessner, C. Walter, M. Hixon, 1996, FEBS letters.

Metabolomics-Based Discovery of Diagnostic Biomarkers for Onchocerciasis

Kim D. Janda, K. Janda, T. Dickerson, 2010, PLoS neglected tropical diseases.

Inhibition of acetyl-coenzyme a carboxylase by coenzyme a conjugates of grass-selective herbicides

M. Hixon, A. Rendina, W. Taylor, 1995 .

Fragment-based drug discovery of potent and selective MKK3/6 inhibitors.

J. Lawson, M. Hixon, C. Grimshaw, 2016, Bioorganic & medicinal chemistry letters.

NB2001, a Novel Antibacterial Agent with Broad-Spectrum Activity and Enhanced Potency against β-Lactamase-Producing Strains

G. Wahl, H. Shepard, M. Hixon, 2002, Antimicrobial Agents and Chemotherapy.

Risk of evolutionary escape from neutralizing antibodies targeting SARS-CoV-2 spike protein

D. Joseph-McCarthy, J. Carlson, A. Chakravarty, 2020, medRxiv.

Identification of a Natural Product Antagonist against the Botulinum Neurotoxin Light Chain Protease.

K. Janda, C. Shoemaker, J. Barbieri, 2010, ACS medicinal chemistry letters.

Design, synthesis and optimization of novel Alk5 (activin-like kinase 5) inhibitors.

J. Lawson, M. Hixon, D. Dougan, 2016, Bioorganic & medicinal chemistry letters.

Noninvasive Urine Biomarker Lateral Flow Immunoassay for Monitoring Active Onchocerciasis

K. Janda, M. Hixon, D. Globisch, 2018, ACS infectious diseases.

Calcium-dependent and -independent interfacial binding and catalysis of cytosolic group IV phospholipase A2.

M. Gelb, M. Hixon, A. Ball, 1998, Biochemistry.

Discovery of acetylcholinesterase peripheral anionic site ligands through computational refinement of a directed library.

A. Olson, A. Beuscher, K. Janda, 2005, Biochemistry.

Identification and characterization of single chain anti-cocaine catalytic antibodies.

K. Janda, G. Kaufmann, K. M. McKenzie, 2007, Journal of molecular biology.

Discovery of novel benzo[b][1,4]oxazin-3(4H)-ones as poly(ADP-ribose)polymerase inhibitors.

M. Hixon, C. Grimshaw, R. de Jong, 2013, Bioorganic & medicinal chemistry letters.

Benzoquinones as inhibitors of botulinum neurotoxin serotype A.

P. T. Bremer, K. Janda, M. Hixon, 2014, Bioorganic & medicinal chemistry.

Chirality holds the key for potent inhibition of the botulinum neurotoxin serotype a protease.

Karen N. Allen, K. Janda, N. Silvaggi, 2010, Organic letters.

Synthetic molecules for disruption of the MYC protein-protein interface.

P. Vogt, K. Janda, M. Hixon, 2018, Bioorganic & medicinal chemistry.

Formulating a new basis for the treatment against botulinum neurotoxin intoxication: 3,4-Diaminopyridine prodrug design and characterization.

K. Janda, M. Hixon, D. Globisch, 2011, Bioorganic & medicinal chemistry.

Toward the discovery of potent inhibitors of botulinum neurotoxin A: development of a robust LC MS based assay operational from low to subnanomolar enzyme concentrations.

K. Janda, M. Hixon, Laura A McAllister, 2008, Chemical communications.

A platform stratifying a sequestering agent and a pharmacological antagonist as a means to negate botulinum neurotoxicity.

K. Janda, M. Hixon, Tyler L. Harris, 2014, ACS chemical neuroscience.

A fragment-based approach to identifying S-adenosyl-l-methionine -competitive inhibitors of catechol O-methyl transferase (COMT).

K. Saikatendu, Louise M. Walsh, G. Ambrus, 2014, Journal of medicinal chemistry.

Probing BoNT/A Protease Exosites: Implications for Inhibitor Design and Light Chain Longevity

K. Janda, Sacha Javor, M. Hixon, 2014, Biochemistry.

In Silico Development of Combinatorial Therapeutic Approaches Targeting Key Signaling Pathways in Metabolic Syndrome

M. Hixon, K. Chakravarty, D. Walden, 2022, Pharmaceutical Research.

A cross-over inhibitor of the botulinum neurotoxin light chain B: a natural product implicating an exosite mechanism of action.

Karen N. Allen, K. Janda, M. Hixon, 2011, Chemical communications.

T-3364366 Targets the Desaturase Domain of Delta-5 Desaturase with Nanomolar Potency and a Multihour Residence Time.

A. Mizukami, M. Hixon, Ikuo Miyahisa, 2016, ACS medicinal chemistry letters.

Monoclonal Antibodies for Combating Synthetic Opioid Intoxication.

P. T. Bremer, K. Janda, M. Hixon, 2019, Journal of the American Chemical Society.

Solid-phase synthesis and kinetic characterization of fluorogenic enzyme-degradable hydrogel cross-linkers.

K. Janda, M. Hixon, Jason Y. H. Chang, 2006, Biomacromolecules.

Botulinum neurotoxin A protease: discovery of natural product exosite inhibitors.

K. Janda, J. Barbieri, M. Hixon, 2010, Journal of the American Chemical Society.

Benzylidene cyclopentenediones: First irreversible inhibitors against botulinum neurotoxin A's zinc endopeptidase.

K. Janda, Eric A. Johnson, J. Barbieri, 2010, Bioorganic & medicinal chemistry letters.

Design, synthesis and optimization of 7-substituted-pyrazolo[4,3-b]pyridine ALK5 (activin receptor-like kinase 5) inhibitors.

J. Lawson, M. Hixon, D. Dougan, 2017, Bioorganic & Medicinal Chemistry Letters.

A simple and widely applicable hit validation strategy for protein-protein interaction inhibitors based on a quantitative ligand displacement assay.

M. Hixon, Ikuo Miyahisa, J. Matsui, 2014, Bioorganic & medicinal chemistry letters.

Synthetic fluorescent MYC probe: Inhibitor binding site elucidation and development of a high-throughput screening assay.

T. Spicer, P. Griffin, P. Vogt, 2021, Bioorganic & medicinal chemistry.

Onchocerca volvulus-neurotransmitter tyramine is a biomarker for river blindness

A. Hoerauf, K. Janda, M. Hixon, 2013, Proceedings of the National Academy of Sciences.

Structures of Clostridium botulinum Neurotoxin Serotype A Light Chain complexed with small-molecule inhibitors highlight active-site flexibility.

Kim D Janda, Saul Tzipori, Nicholas R Silvaggi, 2007, Chemistry & biology.

Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein

D. Joseph-McCarthy, J. Carlson, A. Chakravarty, 2021, PloS one.

Interfacial recognition by bee venom phospholipase A2: insights into nonelectrostatic molecular determinants by charge reversal mutagenesis.

M. Gelb, M. Jain, M. Hixon, 1998, Biochemistry.

Antibody-catalyzed anaerobic destruction of methamphetamine

K. Janda, M. Hixon, P. Wentworth, 2007, Proceedings of the National Academy of Sciences.

Probing the effects of hapten stability on cocaine vaccine immunogenicity.

G. Koob, K. Janda, M. Hixon, 2013, Molecular pharmaceutics.

Probing active cocaine vaccination performance through catalytic and noncatalytic hapten design.

G. Koob, K. Janda, M. Hixon, 2013, Journal of medicinal chemistry.

An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists

D. Boger, K. Janda, Eric A. Johnson, 2007, Proceedings of the National Academy of Sciences.

Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: comparison of binding to non-phosphorylated and phosphorylated VEGFR2.

M. Hixon, S. Imamura, H. Kimura, 2011, Bioorganic & medicinal chemistry.

Repurposing Suzuki Coupling Reagents as a Directed Fragment Library Targeting Serine Hydrolases and Related Enzymes

M. Klein, R. Tjhen, M. Hixon, 2017, Journal of medicinal chemistry.

ATP Allosterically Activates the Human 5-Lipoxygenase Molecular Mechanism of Arachidonic Acid and 5(S)-Hydroperoxy-6(E),8(Z),11(Z),14(Z)-eicosatetraenoic Acid

T. Holman, M. Hixon, Christopher J. Smyrniotis, 2014, Biochemistry.

The Mechanism of Class II, Metal‐Dependent Aldolases

W. Fessner, M. Hixon, J. Schloss, 1996 .

A randomized, double-blind, placebo controlled, phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of LB-102, a selective dopamine D2/3/5-HT7 inhibitor

M. Hixon, A. Vaino, L. Biernat, 2022, Psychopharmacology.

Biochemical characterization of TAK-593, a novel VEGFR/PDGFR inhibitor with a two-step slow binding mechanism.

M. Hixon, S. Imamura, Hidehisa Iwata, 2011, Biochemistry.

Rapid Determination of the Specificity Constant of Irreversible Inhibitors (kinact/KI) by Means of an Endpoint Competition Assay.

M. Hixon, Ikuo Miyahisa, Tomoya Sameshima, 2015, Angewandte Chemie.

Identification of α2 macroglobulin as a major serum ghrelin esterase.

K. Janda, M. Hixon, L. M. Eubanks, 2011, Angewandte Chemie.

Synthesis and application of a novel ligand for affinity chromatography based removal of endotoxin from antibodies.

K. Janda, M. Hixon, Laura A McAllister, 2007, Bioconjugate chemistry.

MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody

J. Lawson, P. Vincent, K. Okada, 2017, Molecular Cancer Therapeutics.

Development of a FRET assay for monitoring of HIV gp41 core disruption.

P. Dawson, K. Janda, M. Hixon, 2007, The Journal of organic chemistry.

The C-terminus of Botulinum A Protease Has Profound and Unanticipated Kinetic Consequences Upon the Catalytic Cleft.

Matthew A. Lardy, K. Janda, C. Shoemaker, 2013, ACS medicinal chemistry letters.

Synthesis, characterization and development of a high-throughput methodology for the discovery of botulinum neurotoxin a inhibitors.

Kim D Janda, Saul Tzipori, Grant E Boldt, 2006, Journal of combinatorial chemistry.

Catalytic antibody degradation of ghrelin increases whole-body metabolic rate and reduces refeeding in fasting mice

E. Zorrilla, K. Janda, M. Meijler, 2008, Proceedings of the National Academy of Sciences.

Combinatorial approaches using an AI/ML-driven drug development platform targeting insulin resistance, lipid dysregulation, and inflammation for the amelioration of metabolic syndrome in patients

M. Hixon, K. Chakravarty, D. Walden, 2021, bioRxiv.

A Back-to-Front Fragment-Based Drug Design Search Strategy Targeting the DFG-Out Pocket of Protein Tyrosine Kinases.

H. Oki, J. Lawson, Terufumi Takagi, 2012, ACS medicinal chemistry letters.

Superactivation of the botulinum neurotoxin serotype A light chain metalloprotease: a new wrinkle in botulinum neurotoxin.

J. P. Kennedy, K. Janda, T. Dickerson, 2006, Journal of the American Chemical Society.

General Method for the Study of Solute-Surfactant Association Equilibria of Volatile Solutes by Head Space Gas Chromatography

M. Hixon, A. Hussam, Z. Olumee, 1995 .

Toward the discovery of dual inhibitors for botulinum neurotoxin A: concomitant targeting of endocytosis and light chain protease activity.

K. Janda, Eric A. Johnson, H. Seki, 2015, Chemical communications.

Antipsychotic Benzamides Amisulpride and LB-102 Display Polypharmacy as Racemates, S Enantiomers Engage Receptors D2 and D3, while R Enantiomers Engage 5-HT7

M. Hixon, A. Vaino, V. Grattan, 2019, ACS omega.

Behavior of a cleptoparasitic bee, Triepeolus distinctus (Hymenoptera: Nomadinae), before departing from the nest of its host, Dieunomia triangulifera (Hymenoptera: Halictidae).

M. Hixon, R. W. Brooks, C. T. Wuellner, 1999 .

NMR detection of adventitious xylose binding to the quorum-sensing protein SdiA of Escherichia coli.

H. Dyson, T. Dickerson, M. Hixon, 2007, Bioorganic & medicinal chemistry letters.

MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody

M. Hixon, P. Farrell, J. Matuszkiewicz, 2017, Molecular Cancer Therapeutics.

T-3364366 Targets the Desaturase Domain of Delta-5 Desaturase with Nanomolar Potency and a Multihour Residence Time.

A. Mizukami, M. Hixon, Ikuo Miyahisa, 2016, ACS medicinal chemistry letters.

Probing active cocaine vaccination performance through catalytic and noncatalytic hapten design.

G. Koob, K. Janda, M. Hixon, 2013, Journal of medicinal chemistry.

ATP Allosterically Activates the Human 5-Lipoxygenase Molecular Mechanism of Arachidonic Acid and 5(S)-Hydroperoxy-6(E),8(Z),11(Z),14(Z)-eicosatetraenoic Acid

T. Holman, M. Hixon, Christopher J. Smyrniotis, 2014, Biochemistry.

Mechanistic insights into the LsrK kinase required for autoinducer-2 quorum sensing activation.

Kim D Janda, K. Janda, G. Kaufmann, 2013, Journal of the American Chemical Society.

A simple and widely applicable hit validation strategy for protein-protein interaction inhibitors based on a quantitative ligand displacement assay.

M. Hixon, Ikuo Miyahisa, J. Matsui, 2014, Bioorganic & medicinal chemistry letters.

Beta-alanine transaminase activity in black and suppressor of black mutations of Drosophila melanogaster.

M. Hixon, J. P. Weber, A. F. Sherald, 1992, Biochimica et biophysica acta.

Targeted Reversible Covalent Modification of a Noncatalytic Lysine of the Krev Interaction Trapped 1 Protein Enables Site-Directed Screening for Protein–Protein Interaction Inhibitors

M. Hixon, C. Ballatore, M. Lopez-Ramirez, 2023, ACS pharmacology & translational science.